Display options
Cite
Shah SB, Hariharan U, Chawla R. Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents. J Anaesthesiol Clin Pharmacol. 2021;37(2):160-170doi: 10.4103/joacp.JOACP_461_20.
Shah, S. B., Hariharan, U., & Chawla, R. (2021). Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents. Journal of anaesthesiology, clinical pharmacology, 37(2), 160-170. https://doi.org/10.4103/joacp.JOACP_461_20
Shah, Shagun B, et al. "Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents." Journal of anaesthesiology, clinical pharmacology vol. 37,2 (2021): 160-170. doi: https://doi.org/10.4103/joacp.JOACP_461_20
Shah SB, Hariharan U, Chawla R. Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents. J Anaesthesiol Clin Pharmacol. 2021 Apr-Jun;37(2):160-170. doi: 10.4103/joacp.JOACP_461_20. Epub 2021 Jul 15. PMID: 34349362; PMCID: PMC8289657.
Copy Download .nbib Format: NLM
Share it on

J Anaesthesiol Clin Pharmacol. 2021 Apr-Jun;37(2):160-170. doi: 10.4103/joacp.JOACP_461_20. Epub 2021 Jul 15.

Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents.

Journal of anaesthesiology, clinical pharmacology

Shagun B Shah, Uma Hariharan, Rajiv Chawla

Affiliations

  1. Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, India.
  2. Dr. Ram Manohar Lohia Hospital and PGIMER, CHS, New Delhi, India.

PMID: 34349362 PMCID: PMC8289657 DOI: 10.4103/joacp.JOACP_461_20

Abstract

The corona virus disease 2019 (COVID-19) pandemic has till date (26/7/20) affected 1crore 62 lac 73 thousand 638 people globally with almost 6.5 lakh mortalities. COVID-19 has invaded the operation theatre and intensive care unit (ICU) in a short span of 6 months. It appears inevitable that all of us, as anesthesiologists, have to treat COVID-positive patients, either in the ICU or the operation theatre. Many asymptomatic, presumably noninfected people including frontline health care workers are also consuming potential anticorona viral drugs (such as hydroxychloroquine) prophylactically and may present for surgery. Detailed knowledge of which anesthetic and perioperative care drugs can interact with anti-COVID drugs would be very valuable for pre, intra-, and postoperative management of such patients and COVID-19 positive patients requiring intubation, mechanical ventilation, and ICU-sedation. Powered with this knowledge, anesthesiologists and intensivists can minimize the adverse effects of drug interactions. An extensive literature search using different search engines including Cochrane, Embase, Google Scholar, Scopus, and PubMed for all indexed review articles, original articles, case reports, and referenced webpages was performed to extract the most current and relevant literature on drug-drug interactions for clinicians.

Copyright: © 2021 Journal of Anaesthesiology Clinical Pharmacology.

Keywords: Anesthetic drugs; COVID-19; azithromycin; dexamethasone; favipiravir; hydroxychloroquine; ivermectin; nitazoxanide; remdesivir; ritonavir; tocilizumab

Conflict of interest statement

There are no conflicts of interest.

References

  1. Drug Saf. 2018 Oct;41(10):919-931 - PubMed
  2. Clin Ther. 2012 Apr;34(4):788-802.e3 - PubMed
  3. Sci Transl Med. 2017 Jun 28;9(396): - PubMed
  4. Biosci Trends. 2020 Mar 16;14(1):72-73 - PubMed
  5. Clin Pharmacokinet. 1987 Jun;12(6):402-32 - PubMed
  6. Eur J Anaesthesiol. 2014 Aug;31(8):417-22 - PubMed
  7. Anaesthesia. 2016 Sep;71(9):1037-43 - PubMed
  8. Br J Clin Pharmacol. 2000 Jun;49(6):549-54 - PubMed
  9. Arch Pharm Res. 2003 Aug;26(8):631-7 - PubMed
  10. Br J Clin Pharmacol. 1994 Feb;37(2):125-8 - PubMed
  11. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975 - PubMed
  12. Ther Drug Monit. 1989;11(4):369-79 - PubMed
  13. Pharmacotherapy. 1998 Jan-Feb;18(1):84-112 - PubMed
  14. Clin Pharmacol Ther. 1982 Mar;31(3):350-7 - PubMed
  15. Arthritis Care Res (Hoboken). 2018 Mar;70(3):481-485 - PubMed
  16. N Engl J Med. 2020 Jun 11;382(24):2327-2336 - PubMed
  17. JAMA. 2003 Apr 23-30;289(16):2120-7 - PubMed
  18. J Electrocardiol. 2018 Mar - Apr;51(2):170-174 - PubMed
  19. J Pharm Sci. 2013 Sep;102(9):2953-94 - PubMed
  20. Inflammation. 2019 Aug;42(4):1336-1349 - PubMed
  21. J Adv Res. 2020 Mar 16;24:91-98 - PubMed
  22. Mutat Res. 2014 Oct;768:16-21 - PubMed
  23. Eur J Pharmacol. 2009 Dec 25;625(1-3):220-33 - PubMed
  24. N Engl J Med. 2004 Mar 4;350(10):1013-22 - PubMed
  25. Xenobiotica. 1998 Mar;28(3):313-21 - PubMed
  26. J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):471-476 - PubMed
  27. Heart. 2003 Nov;89(11):1363-72 - PubMed
  28. mBio. 2018 Mar 6;9(2): - PubMed
  29. Am J Nephrol. 2017;46(5):380-389 - PubMed
  30. Ther Adv Drug Saf. 2016 Jun;7(3):68-78 - PubMed
  31. J Med Toxicol. 2020 Jul;16(3):314-320 - PubMed
  32. Br J Clin Pharmacol. 1999 Jan;47(1):35-42 - PubMed
  33. Pharmacotherapy. 2000 Sep;20(9):1055-9 - PubMed
  34. Lancet. 2005 Feb 19-25;365(9460):682-6 - PubMed
  35. J Clin Psychopharmacol. 2003 Feb;23(1):58-77 - PubMed
  36. Br J Clin Pharmacol. 2015 Nov;80(5):1076-85 - PubMed
  37. JAMA Cardiol. 2020 Sep 1;5(9):1036-1041 - PubMed
  38. Nephron. 1992;62(1):108-9 - PubMed
  39. Anticancer Drugs. 1996 Jul;7(5):568-78 - PubMed
  40. Anesthesiology. 1977 Nov;47(5):471-2 - PubMed
  41. Pharmacol Res. 2016 Sep;111:592-599 - PubMed
  42. Int J Clin Pharmacol Ther. 2015 Oct;53(10):866-74 - PubMed
  43. Int J Antimicrob Agents. 2020 Jul;56(1):105949 - PubMed
  44. Clin Infect Dis. 2005 Apr 15;40(8):1173-80 - PubMed
  45. Anesth Analg. 1996 Jan;82(1):167-72 - PubMed

Publication Types